Paclitaxel nanosomal - Intas Pharmaceuticals

Drug Profile

Paclitaxel nanosomal - Intas Pharmaceuticals

Latest Information Update: 21 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Breast cancer

Most Recent Events

  • 17 Oct 2016 Intas Pharmaceuticals completes a phase II/III trial for Breast cancer (Metastatic disease, Second-line therapy or greater) in India (IV) (CTRI2015-07-006062)
  • 04 Sep 2015 Intas Pharmaceuticals and Jina Pharmaceuticals collaborated in the development of Nanoaqualip™ technology
  • 17 Aug 2015 Phase-II/III clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in India (IV) (CTRI2015-07-006062)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top